Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199017 | 1.00 | TBXAS1 (0.36) | TBXAS1AHRKDM4EALDH1A1CYP17A1 | |
| SCHEMBL4206196 | 0.91 | TBXAS1 (0.38) | TBXAS1AHRKDM4ECYP17A1 | |
| SCHEMBL4206193 | 0.91 | TBXAS1 (0.38) | TBXAS1AHRKDM4ECYP17A1 | |
| SCHEMBL4211619 | 0.87 | TBXAS1 (0.35) | TBXAS1AHRKDM4EALDH1A1KMT2A | |
| SCHEMBL4211623 | 0.87 | TBXAS1 (0.35) | TBXAS1AHRKDM4EALDH1A1KMT2A | |
| SCHEMBL15730995 | 0.87 | TBXAS1 (0.35) | TBXAS1AHRKDM4EALDH1A1KMT2A | |
| SCHEMBL10605367 | 0.83 | BLM (0.40) | TBXAS1KDM4ELMNA | |
| SCHEMBL25635684 | 0.81 | TBXAS1 (0.37) | TBXAS1AHRKDM4EALDH1A1KMT2A | |
| SCHEMBL13102475 | 0.77 | TBXAS1 (0.38) | TBXAS1AHRKDM4EALDH1A1KMT2A | |
| SCHEMBL30935682 | 0.77 | FAAH (0.35) | TBXAS1AHRKDM4EALDH1A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER INC | 2009-10-01 | — | — | US | claimed |
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| EP-1768952-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Warner-Lambert Company LLC (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008612-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | SCN2A, SCN1A, ORAI2 | TBXAS1 968/4885AHR 4304/4885KDM4E 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.